School-based screening and treatment may reduce P. falciparum transmission.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
25 03 2021
Historique:
received: 18 01 2021
accepted: 16 03 2021
entrez: 26 3 2021
pubmed: 27 3 2021
medline: 28 10 2021
Statut: epublish

Résumé

In areas where malaria remains entrenched, novel transmission-reducing interventions are essential for malaria elimination. We report the impact screening-and-treatment of asymptomatic Malawian schoolchildren (n = 364 in the rainy season and 341 in the dry season) had on gametocyte-the parasite stage responsible for human-to-mosquito transmission-carriage. We used concomitant household-based surveys to predict the potential reduction in transmission in the surrounding community. Among 253 students with P. falciparum infections at screening, 179 (71%) had infections containing gametocytes detected by Pfs25 qRT-PCR. 84% of gametocyte-containing infections were detected by malaria rapid diagnostic test. While the gametocyte prevalence remained constant in untreated children, treatment with artemether-lumefantrine reduced the gametocyte prevalence (p < 0.0001) from 51.8 to 9.7% and geometric mean gametocyte density (p = 0.008) from 0.52 to 0.05 gametocytes/microliter. In community surveys, 46% of all gametocyte-containing infections were in school-age children, who comprised only 35% of the population. Based on these estimates six weeks after the intervention, the gametocyte burden in the community could be reduced by 25-55% depending on the season and the measure used to characterize gametocyte carriage. Thus, school-based interventions to treat asymptomatic infections may be a high-yield approach to not only improve the health of schoolchildren, but also decrease malaria transmission.

Identifiants

pubmed: 33767384
doi: 10.1038/s41598-021-86450-5
pii: 10.1038/s41598-021-86450-5
pmc: PMC7994823
doi:

Substances chimiques

Antimalarials 0
Artemether, Lumefantrine Drug Combination 0

Types de publication

Clinical Trial Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

6905

Subventions

Organisme : NIAID NIH HHS
ID : K24 AI114996
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI089683
Pays : United States
Organisme : NIAID NIH HHS
ID : K23 AI135076
Pays : United States

Références

Malar J. 2016 Feb 29;15:127
pubmed: 26928321
BMC Public Health. 2009 Oct 01;9:369
pubmed: 19796380
Lancet Glob Health. 2020 Dec;8(12):e1499-e1511
pubmed: 33222799
PLoS Med. 2016 Nov 22;13(11):e1002175
pubmed: 27875528
PLoS One. 2014 Oct 07;9(10):e107700
pubmed: 25290939
BMJ Glob Health. 2017 Jun 28;2(2):e000182
pubmed: 29081992
Br Med J. 1951 May 19;1(4715):1114-7
pubmed: 14830852
Ann Trop Med Parasitol. 1985 Dec;79(6):549-62
pubmed: 3914860
Trans R Soc Trop Med Hyg. 1995 Nov-Dec;89(6):629-33
pubmed: 8594677
PLoS Med. 2017 Nov 30;14(11):e1002456
pubmed: 29190300
PLoS One. 2016 Jun 09;11(6):e0156717
pubmed: 27281028
PLoS Med. 2017 Nov 30;14(11):e1002452
pubmed: 29190279
J Infect Dis. 2016 Jan 1;213(1):90-9
pubmed: 26142435
Malar J. 2016 Nov 4;15(1):527
pubmed: 27809907
Malar J. 2017 Nov 09;16(1):456
pubmed: 29121931
Malar J. 2015 Dec 30;14:528
pubmed: 26714465
Lancet Glob Health. 2018 Jun;6(6):e668-e679
pubmed: 29661635
Malar J. 2018 Apr 3;17(1):147
pubmed: 29615044
J Infect Dis. 2006 Aug 1;194(3):276-85
pubmed: 16826474
Nat Commun. 2017 Oct 26;8(1):1133
pubmed: 29074880
PLoS One. 2015 Jul 24;10(7):e0134061
pubmed: 26207758
Elife. 2018 May 31;7:
pubmed: 29848446
Nat Rev Microbiol. 2014 Dec;12(12):833-40
pubmed: 25329408
Trends Parasitol. 2015 Jul;31(7):287-96
pubmed: 25985898
Trop Med Int Health. 2014 Nov;19(11):1294-309
pubmed: 25145389
Malar J. 2008 Jul 08;7:123
pubmed: 18611271
Malar J. 2016 Aug 19;15(1):421
pubmed: 27543112

Auteurs

Lauren M Cohee (LM)

Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, 21201, USA. lcohee@som.umaryland.edu.

Clarissa Valim (C)

Department of Global Health, Boston University School of Public Health, Boston, MA, USA.

Jenna E Coalson (JE)

Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, USA.
Eck Institute for Global Health, University of Notre Dame, Notre Dame, IN, USA.

Andrew Nyambalo (A)

Blantyre Malaria Project, University of Malawi College of Medicine, Blantyre, Malawi.

Moses Chilombe (M)

Malaria Alert Center, University of Malawi College of Medicine, Blantyre, Malawi.

Andrew Ngwira (A)

Malaria Alert Center, University of Malawi College of Medicine, Blantyre, Malawi.

Andy Bauleni (A)

Malaria Alert Center, University of Malawi College of Medicine, Blantyre, Malawi.

Karl B Seydel (KB)

Blantyre Malaria Project, University of Malawi College of Medicine, Blantyre, Malawi.
College of Osteopathic Medicine, Michigan State University, East Lansing, MI, USA.

Mark L Wilson (ML)

Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, USA.

Terrie E Taylor (TE)

Blantyre Malaria Project, University of Malawi College of Medicine, Blantyre, Malawi.
College of Osteopathic Medicine, Michigan State University, East Lansing, MI, USA.

Don P Mathanga (DP)

Malaria Alert Center, University of Malawi College of Medicine, Blantyre, Malawi.

Miriam K Laufer (MK)

Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH